<?xml version='1.0' encoding='utf-8'?>
<document id="24291757"><sentence text="Inhibition of human organic cation transporters by the alkaloids matrine and oxymatrine."><entity charOffset="55-72" id="DDI-PubMed.24291757.s1.e0" text="alkaloids matrine" /><entity charOffset="77-87" id="DDI-PubMed.24291757.s1.e1" text="oxymatrine" /><pair ddi="false" e1="DDI-PubMed.24291757.s1.e0" e2="DDI-PubMed.24291757.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24291757.s1.e0" e2="DDI-PubMed.24291757.s1.e1" /></sentence><sentence text="Human organic cation transporters (hOCTs; SLC22) are expressed in many organs, including intestine, liver, kidney, heart and brain, where they contribute to the absorption, distribution, and elimination of endogenous and exogenous substances" /><sentence text=" The alkaloids matrine and oxymatrine are widely used in herbal medicine for the treatment of cancer, as well as viral, and cardiac diseases"><entity charOffset="5-22" id="DDI-PubMed.24291757.s3.e0" text="alkaloids matrine" /><entity charOffset="27-37" id="DDI-PubMed.24291757.s3.e1" text="oxymatrine" /><pair ddi="false" e1="DDI-PubMed.24291757.s3.e0" e2="DDI-PubMed.24291757.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24291757.s3.e0" e2="DDI-PubMed.24291757.s3.e1" /></sentence><sentence text=" Their physicochemical properties indicated that they are potential inhibitors for hOCTs, leading to drug-drug interactions in vivo" /><sentence text=" Therefore, we assessed the inhibitory effects of matrine and oxymatrine on the function of hOCT1 (SLC22A1), hOCT2 (SLC22A2) and hOCT3 (SLC22A3) using stably transfected transporter-expressing cells"><entity charOffset="50-57" id="DDI-PubMed.24291757.s5.e0" text="matrine" /><entity charOffset="62-72" id="DDI-PubMed.24291757.s5.e1" text="oxymatrine" /><pair ddi="false" e1="DDI-PubMed.24291757.s5.e0" e2="DDI-PubMed.24291757.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24291757.s5.e0" e2="DDI-PubMed.24291757.s5.e1" /></sentence><sentence text=" At 100-fold excess, oxymatrine exhibited marked inhibition of hOCT1-mediated substrate uptake (p&lt;0"><entity charOffset="21-31" id="DDI-PubMed.24291757.s6.e0" text="oxymatrine" /></sentence><sentence text="05), while matrine failed to produce significant inhibition on hOCT1"><entity charOffset="11-18" id="DDI-PubMed.24291757.s7.e0" text="matrine" /></sentence><sentence text=" The IC50 value for oxymatrine on hOCT1 was estimated as 513±132 μM"><entity charOffset="20-30" id="DDI-PubMed.24291757.s8.e0" text="oxymatrine" /></sentence><sentence text=" While there was no significant inhibition of hOCT2 or hOCT3 at 100-fold excess, oxymatrine and matrine showed 42% and 88% inhibition of hOCT3-mediated substrate uptake at 3 and 6mM, respectively"><entity charOffset="81-91" id="DDI-PubMed.24291757.s9.e0" text="oxymatrine" /><entity charOffset="96-103" id="DDI-PubMed.24291757.s9.e1" text="matrine" /><pair ddi="false" e1="DDI-PubMed.24291757.s9.e0" e2="DDI-PubMed.24291757.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24291757.s9.e0" e2="DDI-PubMed.24291757.s9.e1" /></sentence><sentence text=" Considering the potential intestinal lumen and reported plasma concentrations of matrine and oxymatrine, these data suggest that drug-drug interactions may occur during hOCT1-mediated hepatic and renal uptake and during hOCT3-mediated intestinal absorption"><entity charOffset="82-89" id="DDI-PubMed.24291757.s10.e0" text="matrine" /><entity charOffset="94-104" id="DDI-PubMed.24291757.s10.e1" text="oxymatrine" /><pair ddi="false" e1="DDI-PubMed.24291757.s10.e0" e2="DDI-PubMed.24291757.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24291757.s10.e0" e2="DDI-PubMed.24291757.s10.e1" /></sentence><sentence text="" /></document>